Seattle-based PathoGenesis Corp. develops and commercializes drugs to treat chronic infectious diseases - particularly serious lung infections, including those common in cystic fibrosis, bronchiectasis and ventilator patients. PathoGenesis' stock is traded on the Nasdaq National Market System under the symbol PGNS.
| Website | http://www.pathogenesis.com |
| Revenue | $201000 |
| Employees | View employees |
| Address | 201 Elliott Ave W Ste 150, Seattle, Washington 98119, US |
| Phone | +1 206-467-8100 |
| Fax | (206) 282-5065 |
| Industry | Business Services General, Business Services |
| Competitors | Genentech, Amgen, Gilead Sciences, Biogen, Regeneron, Vertex Pharmaceuticals, Novo Nordisk, Lilly India, Bristol Myers Squibb, Receptos, a wholly-owned subsidiary of Celgene +44 more (view full list) |
| SIC | SIC Code 73 Companies, SIC Code 737 Companies |
| NAICS | NAICS Code 5415 Companies, NAICS Code 541 Companies, NAICS Code 541511 Companies, NAICS Code 54151 Companies, NAICS Code 54 Companies |
Looking for a particular PathoGenesis Corporation employee's phone or email?
PathoGenesis Corporation Questions
The PathoGenesis Corporation annual revenue was $201000 in 2026.
PathoGenesis Corporation is based in Seattle, Washington.
The NAICS codes for PathoGenesis Corporation are [5415, 541, 541511, 54151, 54].
The SIC codes for PathoGenesis Corporation are [73, 737].
